With homegrown pipeline set to reach clinic, Roivant chooses Patient Square’s SPAC as vehicle to NASDAQ

A merger between Roivant and a SPAC sponsored by Patient Square will create a publicly traded umbrella company with $2.3 billion to put toward drug discovery, in-licensing and development, including its first program due to reach the clinic from its nascent protein degradation pipeline.

Roivant Sciences Ltd. and blank-check company Montes Archimedes Acquisition Corp. (NASDAQ:MAAC) will merge in a deal that is to close next quarter, keeping the Roivant name and top management including Chairman Vivek Ramaswamy and CEO Matthew Gline...